Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
23 hedge funds and large institutions have $40.2M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 27 → 23 (-4)
19% less capital invested
Capital invested by funds: $49.6M → $40.2M (-$9.37M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$63K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$3.96M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$2.5M |
| 3 |
GCL
Glazer Capital LLC
New York
|
-$2.11M |
| 4 |
Millennium Management
New York
|
-$1.35M |
| 5 |
Walleye Capital
New York
|
-$1.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Millennium Management
New York
| – | -$1.35M | -134,735 | Closed |
|
27
Walleye Trading
New York
| – | -$800K | -80,000 | Closed |
|
|
HP
28
Hound Partners
New York
| – | -$498K | -49,867 | Closed |
|
|
EH
29
EMG Holdings
Old Greenwich,
Connecticut
| – | -$100K | -10,000 | Closed |
|
|
CS
30
Clear Street
New York
| – | +$409 | +41 | New |
|
IBER.U Hedge Fund Activity: Q4 2021 in Review
23 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q4 2021, worth a combined $40.2M — down 19% from $49.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IBER.U and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Janus Henderson Group, adding an estimated $63K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $3.96M sold.
- 23 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q4 2021, down from 27 in Q3 2021.
- Funds reported $40.2M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q4 2021, down 19% quarter-over-quarter.
- 4 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q4 2021 and 7 closed out, a net change of -3 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q4 2021 was Janus Henderson Group, an estimated $63K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q4 2021 was Shaolin Capital Management, an estimated $3.96M sold.
Based on aggregated 13F filings for Q4 2021.